Sarah Yentz, MD

 Sarah Yentz, MD
Associate Program Director, Internal Medicine Residency
Clinical Associate Professor of Internal Medicine
Medical School
University of Michigan, Michigan Medicine
Internal Medicine
1500 E Medical Center Dr., C426 MIB
Ann Arbor, MI 48109
[email protected]
Available to mentor
Sarah Yentz, MD
Sarah Yentz, MD
Clinical Associate Professor
  • About
  • Links
  • Qualifications
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Dr. Sarah Yentz received her medical degree from the University of Michigan and completed Internal Medicine residency training at Northwestern Memorial Hospital where she served as chief resident 2014-2015. She completed her fellowship in Hematology/Oncology at the University of Michigan in 2018. She has a joint appointment with the Ann Arbor VA Hospital. She is interested in medical education and serves as an associate program director for the internal medicine residency program and teaches first year medical students as part of the medical school "Doctoring" program.

    Links
    • Sarah Yentz, MD
    • Sarah Yentz, MD Rogel Cancer Center

    Qualifications
    • Fellowship Hematology/Oncology
      University of Michigan Medical School, Internal Medicine, Ann Arbor, United States
      2015 - 2018
      Postdoctoral Fellowship
    • Chief Resident
      Northwestern Medicine, Chicago, United States
      2014 - 2015
      Postdoctoral Fellowship
    • Residency
      Northwestern Medicine, Internal Medicine, Chicago, United States
      2011 - 2014
      Residency

    Research Overview

    Medical Education
    Quality Improvement
    Clinical Research in Genitourinary Oncology and Melanoma

    Recent Publications

     See All Publications
    • Proceeding / Abstract / Poster
      ICON trial: Phase I/II trial of inulin gel in combination with ipilimumab and nivolumab in advanced renal cell.
      Yentz S, Rice J, Tsung I, Caram MV, Palmbos P, Reasoner D, Vaishampayan U. 2026 Mar 1;
    • Proceeding / Abstract / Poster
      Impact of abiraterone versus enzalutamide on depression and anxiety in hormonesensitive prostate cancer (HSPC).
      Tsao P, Urban-Wojcik E, Seewald M, Khan A, Bryant A, Palmbos PL, Smith DC, Tsung I, Vaishampayan U, Yentz SE, Alumkal J, Reichert Z, Caram MV. Clinical Oncology, 2026 Mar 2; 44 (147):
    • Preprint
      Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)
      Vaishampayan U, Taylor JMG, Kilari D, Dorff T, Sokolava A, Huang Y, Palmbos P, Brown J, Tsung I, Caram M, Yentz S, Nazha B, Reichert Z, Alumkal J. 2026 Apr 24; Research Square, DOI:10.21203/rs.3.rs-9471666/v1
    • Presentation
      Michigan Medicine GU Cancer Symposium
      Yentz S. 2026 Jun 15;
    • Journal Article
      Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).
      Tsung I, Smith DC, Heath EI, Cackowski F, Devitt ME, Braun TM, Yentz S, Nguyen CB, Chinnaiyan AM, Shah N, Smith S, Dean E, Vaishampayan U, Caram MEV, Palmbos P, Alumkal JJ, Reichert ZR. JCO Precis Oncol, 2025 Sep; 9: e2500457 DOI:10.1200/PO-25-00457
      PMID: 40956994
    • Journal Article
      Controversies in metastatic hormone-sensitive prostate cancer.
      Tsung I, Yentz SE, Reichert ZR. Cancer, 2025 Aug 15; 131 (16): e70030 DOI:10.1002/cncr.70030
      PMID: PMC12330319
    • Presentation
      UT Southwestern Hospital Medicine Grand Rounds: AI in Action: Leveraging New Technologies for Internal Medicine Educators (Vitrual)
      Yentz S. 2025 Jul 17;